Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Ultraviolet Light Therapy for Systemic Lupus Erythematosus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2004 by National Center for Research Resources (NCRR).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Louisiana State University Health Sciences Center in New Orleans
Information provided by:
National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:
NCT00004375
First received: October 18, 1999
Last updated: June 23, 2005
Last verified: January 2004
  Purpose

OBJECTIVES:

I. Evaluate the mechanisms of ultraviolet A-1 light therapy in patients with systemic lupus erythematosus and normal controls.


Condition Intervention Phase
Systemic Lupus Erythematosus
Procedure: ultraviolet A-1 light treatment
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Center for Research Resources (NCRR):

Estimated Enrollment: 20
Study Start Date: September 1991
Detailed Description:

PROTOCOL OUTLINE:

Treatment with ultraviolet A-1 light is administered 5 days a week for 6 weeks, at the lowest dose or frequency required to maintain a response. The dose and frequency are progressively decreased over the next 9 weeks.

  Eligibility

Ages Eligible for Study:   15 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Patients ages 15 to 70 with symptomatic systemic lupus erythematosus meeting American Rheumatism Association criteria and normal controls

--Prior/Concurrent Therapy--

No requirement for tetracycline or other photosensitizing drugs

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004375

Locations
United States, Louisiana
Alton Ochsner Medical Foundation Hospital Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Jawed Alam    504-842-3314      
General Clinical Research Center and Charity Hospital (University of Louisiana) Recruiting
New Orleans, Louisiana, United States, 70112-2822
Contact: Hugh McGrath, Jr.    504-568-4630    hmcgra@lsuhsc.edu   
Sponsors and Collaborators
Louisiana State University Health Sciences Center in New Orleans
Investigators
Study Chair: Hugh McGrath, Jr. Louisiana State University Health Sciences Center in New Orleans
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00004375     History of Changes
Other Study ID Numbers: NCRR-M01RR05096-0002, LSUMC-1765, LSUMC-910067
Study First Received: October 18, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by National Center for Research Resources (NCRR):
arthritis & connective tissue diseases
immunologic disorders and infectious disorders
rare disease
systemic lupus erythematosus

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on November 23, 2014